How to buy DexCom stock (DXCM)

DexCom is a medical devices business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $77.19 – a decrease of 0.68% over the previous week. DexCom employs 9,500 staff and has a trailing 12-month revenue of around $4 billion.

Our top picks for where to buy DexCom stock

Buy DexCom stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

DexCom stock price (NASDAQ: DXCM)

Use our graph to track the performance of DXCM stocks over time.

DexCom shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$77.19
52-week range	$62.34 - $142.00
50-day moving average more info button	$72.80
200-day moving average more info button	$99.30
Wall St. target price	$95.93
PE ratio more info button	48.7697
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.65

Is it a good time to buy DexCom stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DexCom price performance over time

Historical closes compared with the close of $77.19 from 2024-12-13

1 week (2024-12-06)	-0.68%
1 month (2024-11-15)	1.73%
3 months (2024-09-13)	11.05%
6 months (2024-06-14)	-33.43%

1 year (2023-12-15)	-37.03%
2 years (2022-12-15)	-33.59%
3 years (2021-12-15)	135.3225
5 years (2019-12-13)	51.48%

Is DexCom stock undervalued or overvalued?

Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DexCom's P/E ratio

DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, DexCom shares trade at around 49x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

DexCom's PEG ratio

DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2416. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

DexCom's EBITDA

DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $840.4 million.

The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.

DexCom financials

Revenue TTM	$4 billion
Operating margin TTM	15.29%
Gross profit TTM	$1.9 billion
Return on assets TTM	6.06%
Return on equity TTM	32.06%
Profit margin	17.22%
Book value	$5.07
Market Capitalization more info button	$31.4 billion

TTM: trailing 12 months

DexCom share dividends

We're not expecting DexCom to pay a dividend over the next 12 months.

Have DexCom's shares ever split?

DexCom's shares were split on a 4:1 basis on 12 June 2022 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your DexCom shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for DexCom shares which in turn could have impacted DexCom's share price.

DexCom share price volatility

Over the last 12 months, DexCom's shares have ranged in value from as little as $62.34 up to $142. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 1.173. This would suggest that DexCom's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

DexCom overview

DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators.

Frequently asked questions

What percentage of DexCom is owned by insiders or institutions?
Currently 0.315% of DexCom shares are held by insiders and 97.138% by institutions. How many people work for DexCom?
Latest data suggests 9,500 work at DexCom. When does the fiscal year end for DexCom?
DexCom's fiscal year ends in December. Where is DexCom based?
DexCom's address is: 6340 Sequence Drive, San Diego, CA, United States, 92121 What is DexCom's ISIN number?
DexCom's international securities identification number is: US2521311074 What is DexCom's CUSIP number?
DexCom's Committee on Uniform Securities Identification Procedures number is: 252131107